

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 5, 2021
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 5, 2021.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Kimberly Rudd, MD
Cheryl Hartvigsen, RPh
Erika Tillery, PharmD

Edward Behling, MD
Kenric Ware, PharmD
Thomas Phillips, RPh
Patricia Witherspoon, MD

Duncan Norton, MD
Phillip Mubarak, MD
Gregory Browning, MD
Kelly Barth, MD

SC DHHS Staff:

Robert Kerr
Janelle Smith
Nicole Wetherton, JD
Janet Giles
Michael Psikogios, MD
Ashley Sirianni, DNP, FNP-BC

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 3, 2021

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Biohaven	Chelsea Leroue, PhD	Anti-migraine: CGRP blockers/modulators (Oral)
AbbVie	Andrea Hume, MD	Anti-migraine: CGRP blockers/modulators (Oral)
Lilly	Mark Borns, PharmD	Glucagon Agents
PRISMA Health	Elaine Apperson, MD	Glucagon Agents
Lilly	Mark Borns, PharmD	Hypoglycemic Incretin Mimetic/GLP1 Inj
NovoNordisk	Tammy Kell, PharmD	Hypoglycemic Incretin Mimetic/GLP1 Inj

C. Drug Classes for Review

Classes for Review

Anti-Migraine (CGRP Blockers/Modulators)(Oral)

Glucagon Agents (**No changes will be made to the Class at this time.**)

Classes for Re-Review

Androgenic Agents (Transdermal)

Hypoglycemic Incretin Mimetic (GLP1 receptor agonists/combo)(Inj)

Insulins (Inj)

The chart below represents the recommendations from the P & T Committee:

ANTI-MIGRAINE: CGRP BLOCKERS/MODULATORS - ORAL	
Preferred	Non-Preferred
Ubrelvy‡	Nurtec, ODT ⁺
GLUCAGON AGENTS	
Preferred	Non-Preferred
Baqsimi (Nasal)‡	Diazoxide Suspension (Oral)
Proglycem Suspension (oral)‡	Glucagon Emergency Kit Inj (Fresenius)
Glucagon Inj‡	
Glucagon Emergency Kit Inj (Lilly)‡	
Gvoke Pen/Syringe	
ANDROGENIC AGENTS - TRANSDERMAL	
Preferred	Non-Preferred
Androgel pump	Androderm
	Androgel Packets ⁺
	Fortesta
	Testim
	Vogelxo

	Xyosted
HYPOGLYCEMIC INCRETIN MIMETIC/GLP-1RA, INJECTABLES	
Preferred	Non-Preferred
Trulicity‡	Adlyxin
Victoza	Byetta
	Bydureon ⁺
	Ozempic
	Soliqua
	Xultophy
INSULIN: RAPID ACTING, INJECTABLES	
Preferred	Non-Preferred
Apidra Solostar Pen‡	Admelog
Humalog	Apidra vial
Novolog	Fiasp pen/Flextouch/vial
	Lyumjev
INSULIN: SHORT-INTERMEDIATE, INJECTABLES	
Preferred	Non-Preferred
Humulin N	Novolin N/R
Humulin R	ReliOn
Humulin R U-500‡	
INSULIN: LONG ACTING, INJECTABLES	
Preferred	Non-Preferred
Lantus	Basalgar
Levemir	Semglee
	Toujeo
	Tresiba
INSULIN: PRE-MIXED COMBINATIONS, INJECTABLES	
Preferred	Non-Preferred
Humalog 50/50	Novolin 70/30
Humalog 75/25 (insulin lispro/proamatinine mix AG‡)	Novolog 70/30 vial OTC
Humulin 70/30	
Novolog 70/30 mix (insulin aspart/insulin aspart proamatinine AG‡)	

- ‡ Added as “Preferred”
- + Moved to “Non-Preferred”

5. **Old Business**
None

6. **New Business**
Janelle Smith, Deputy Director, introduced SC’s new Medicaid Director, Robert Kerr. Lisa presented new drugs to market.

7. **Resolved Items**

Classes for Review

Anti-Migraine (CGRP Blockers/Modulators – Oral)

Glucagon Agents (***No changes will be made to the Class at this time.***)

Classes for Re-Review

Androgenic Agents (Transdermal)

Hypoglycemic Incretin Mimetic (GLP1 receptor agonists/combo)(Inj)

Insulins (Inj)

8. **Closing Comments**

The next meeting will be held Wednesday, August 4, 2021.

9. **Adjournment**

The meeting adjourned at 5:40 p.m.